RPE65 and retinal disorder: In 2001, Acland et al described successful gene therapy in Briard dogs with RPE65-retinopathy using subretinal delivery of recombinant adeno-associated virus serotype 2 (AAV2) vector with canine RPE65 cDNA under the control of the cytomegalovirus chicken beta actin promoter.39 Injected eyes of these dogs showed improved ERG, pupillometry and flash evoked cortical potentials in the dark-adapted state.